Search research articles
Contact Us
Filters
Showing results (41-50 of 80) with videos related to
Page
of 8
Sort By:
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
JAMA Oncology
|
May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
Tafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
Nature Communications
|
July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
JAMA Oncology
|
November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
The Oncologist
|
August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 80) with videos related to
Sort By:
Page
of 8
Cancer Cell
|
September 29, 2023
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu, Jiwoong Kim, Qing Deng, et al.
JAMA Oncology
|
June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
Alessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
JAMA Oncology
|
May 23, 2024
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
Tafadzwa L Chaunzwa, Jack M Qian, Qin Li, et al.
Nature Communications
|
July 15, 2023
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V Alessi, Biagio Ricciuti, Xinan Wang, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
A Di Federico, S L Alden, J W Smithy, et al.
JAMA Oncology
|
November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
The Oncologist
|
August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Page
of 8